Uro-pain Tablet
NDC 57237-331
Product Information
Uro-pain (phenazopyridine hydrochloride) is a UNAPPROVED DRUG OTHER-approved product labeled by Rising Pharma Holdings, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a red tablet for oral administration. This product entry covers the primary NDC 57237-331 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
P
Code Structure Chart
Product Details
What is NDC 57237-331?
What are the uses of this product?
What are Active Ingredients of this product?
- PHENAZOPYRIDINE HYDROCHLORIDE 95 mg/1 - A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PHENAZOPYRIDINE HYDROCHLORIDE (UNII: 0EWG668W17)
- PHENAZOPYRIDINE (UNII: K2J09EMJ52) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- STARCH, CORN (UNII: O8232NY3SJ)
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)
- CARNAUBA WAX (UNII: R12CBM0EIZ)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1094126 - phenazopyridine HCl 95 MG Oral Tablet
- RxCUI: 1094126 - phenazopyridine hydrochloride 95 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.